Carol Addy - Concepedia

Author

Carol Addy

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

C Addy, C. Addy, C. L. Addy, Carol Addy, Carol L. Addy

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)United States Military Academy Washington Center for Weight Management and Research Beth Israel Deaconess Medical Center Johnson & Johnson (United States)

About

Carol Addy is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, metabolic syndrome, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	1.4K
2	Health Sciences	5	5	1.1K
3	Management	1	1	42
4	Public Health	1	1	42
5	Biochemistry	1	1	400

Carol Addy

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation Chai-Wan Kim, Carol Addy, Jun Kusunoki, Cell Metabolism Metabolic SyndromeHepatologyBiochemistryLipid SynthesisBench Investigation	2017	400
Plasma Adiponectin Concentrations in Relation to Endometrial Cancer: A Case-Control Study in Greece Eleni Petridou, Christos S. Mantzoros, Nick Dessypris, The Journal of Clinical Endocrinology & Metabolism Metabolic SyndromeEndocrine OncologyMedicinePathologyGynecology	2003	232
Hypoadiponectinemia Is Associated with Insulin Resistance, Hypertriglyceridemia, and Fat Redistribution in Human Immunodeficiency Virus-Infected Patients Treated with Highly Active Antiretroviral Therapy Carol Addy, Alina Gavrila, Sotirios Tsiodras, The Journal of Clinical Endocrinology & Metabolism Metabolic DisorderObesityMetabolic SyndromeBody CompositionFat Redistribution	2003	220
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis Kris V. Kowdley, Christopher L. Bowlus, Cynthia Levy, New England Journal of Medicine	2023	213
The Acyclic CB1R Inverse Agonist Taranabant Mediates Weight Loss by Increasing Energy Expenditure and Decreasing Caloric Intake Carol Addy, Hamish Wright, Koen Van Laere, Cell Metabolism ObesityMetabolic SyndromeCaloric RestrictionEnergy MetabolismEnergy Homeostasis	2008	200
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults Ngozi Erondu, Ira Gantz, Bret J. Musser, Cell Metabolism ObesityMetabolic SyndromeMeaningful Weight LossPhysiologyObesity Management	2006	181
Single‐Dose Administration of MK‐0657, an NR2B‐Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease Carol Addy, C. Assaid, David Hreniuk, The Journal of Clinical Pharmacology Nr2b‐selective Nmda AntagonistNeurological ProgressClinical NeurosciencePharmacotherapyGlutamatergic Activity	2009	61
Recombinant Methionyl Human Leptin Administration to Achieve High Physiologic or Pharmacologic Leptin Levels Does Not Alter Circulating Inflammatory Marker Levels in Humans with Leptin Sufficiency or Excess Jean L. Chan, John W. Bullen, Violeta Stoyneva, The Journal of Clinical Endocrinology & Metabolism	2005	61
Multiple‐Dose Pharmacokinetics, Pharmacodynamics, and Safety of Taranabant, a Novel Selective Cannabinoid‐1 Receptor Inverse Agonist, in Healthy Male Volunteers Carol Addy, Paul Rothenberg, Susie Li, The Journal of Clinical Pharmacology Accumulation Half-lifePharmacotherapyMultiple-dose PharmacokineticsExperimental PharmacologyCannabinoid Pharmacology	2008	49
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Taranabant, a Novel Selective Cannabinoid‐1 Receptor Inverse Agonist, for the Treatment of Obesity: Results From a Double‐Blind, Placebo‐Controlled, Single Oral Dose Study in Healthy Volunteers Carol Addy, Susie Li, Nancy Agrawal, The Journal of Clinical Pharmacology	2008	47

Page 1